TrialBritish journal of haematology2012

Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.

Taiga Nishihori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.